1 / 8

Hemophilia Treatment Market to Rake US$ 20,507.92 million by 2027

Hemophilia is a hereditary genetic blood disorder that affects the capacity of the blood to clot due to the lack of a particular protein needed for blood clotting. The hemophilia is graded as Hemophilia A, Hemophilia B, and C. Many recombinant drugs, such as an antihemophilic factor or Factor VII, are injectable.<br><br>Read More:- https://www.theinsightpartners.com/reports/hemophilia-treatment-market

Karan45
Télécharger la présentation

Hemophilia Treatment Market to Rake US$ 20,507.92 million by 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia Treatment Market Global Analysis and Forecast to 2027 Published Date : Feb 2020 Email: sales@theinsightpartners.com

  2. Email:sales@theinsightpartners.com Report Studies • Hemophilia Treatment Market to 2027 - Global Analysis and Forecasts by Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents); Disease (Hemophilia A, Hemophilia B, Hemophilia C); Treatment Type (On-demand, Prophylaxis); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, Antibody Therapy); End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others), and Geography

  3. Email:sales@theinsightpartners.com Hemophilia Treatment Market Value CAGR of 6.1% (2020 to 2027)

  4. Email:sales@theinsightpartners.com Hemophilia Treatment Market Overview • The Hemophilia Treatment Market was valued at US$ 12,797.36 million in 2019 and it is projected to reach US$ 20,507.92 million in 2027; it is expected to grow at a CAGR of 6.1% from 2020 to 2027. • Hemophilia is a hereditary genetic blood disorder that affects the capacity of the blood to clot due to the lack of a particular protein needed for blood clotting.

  5. Email:sales@theinsightpartners.com Key Segment Market Segment By Type:- • Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents) • Disease (Hemophilia A, Hemophilia B, Hemophilia C) • Treatment Type (On-demand, Prophylaxis) • Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, Antibody Therapy) • End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others)

  6. Email:sales@theinsightpartners.com Company Profiles • Bayer AG • Sanofi • F. Hoffmann-la Roche Ltd. • Kedrion S.P.A. • CSL Limited • Biotest AG • Pfizer Inc. • Novo Nordisk A/S • Octapharma AG • Baxter International Inc. Download Sample Here

  7. Email:sales@theinsightpartners.com By Geography • North America (the US, Canada, and Mexico) • Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe) • Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific) • Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa) • South & Central America (Brazil, Argentina, and the Rest of South & Central America).

  8. THANKYOU! Phone : +1-646-491-9876 E-Mail : sales@theinsightpartners.com

More Related